Specialty Pharmacy

Doctors are less likely to prescribe common cardiovascular prevention and intervention therapies to HIV-positive patients.

Medication histories taken by pharmacists and pharmacy technicians significantly reduced medication errors.

Starting an adherence program for patients with HIV may mitigate costs for universal treatment protocols.

Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.

Cell structure may allow immune cells to attack myelin in multiple sclerosis.

Top news of the day from across the health care landscape.

Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.

Age-related health issues affect people living with HIV infection at an accelerated rate.

Bevacizumab (Avastin) previously received provisional approval from the FDA.

A new report suggests Amazon is in talks with Mylan and Sandoz.

Another study suggests gut bacteria has an important role in triggering multiple sclerosis.

The FDA previously found that PD-1/PD-L1 inhibitors may increase the mortality risk for patients with multiple myeloma.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses the importance of specialty pharmacists becoming certified and how it improves the industry as a whole.

Pharmacy professionals must embrace a number of changes in technology.

Independent pharmacies must stay on top of developing trends across the specialty pharmacy landscape.

The CVS-Aetna acquisition could have several implications for pharmacies and patients.

Genetically engineering the gut microbiome may hold the key to treating Crohn’s disease.

Patients receiving adjuvant chemotherapy are at a high risk of new persistent opioid use.

Top news of the day from across the health care landscape.

Centers for Medicare & Medicaid Services proposed national coverage determination of the FoundationOne CDx test.

Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.

Evolocumab (Repatha) is the only PCSK9 inhibitor approved to prevent heart attack, stroke, and coronary revascularization.

FDA plans to further expedite novel treatments under the 21st Century Cures Act.

A second HIV test may avoid significant costs.

Development of tirasemtiv halted due to poor performance in a late-stage clinical trial.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

Joel Wright, chief executive officer, AllianceRx Walgreens Prime discusses how specialty pharmacies can leverage retail pharmacies connections to negotiate costs.